A new era of cancer immunotherapy has begun. Chimeric antigen receptor T (CAR-T) cells, which have been genetically engineered to recognize the CD-19 antigen of B cells, have been successfully treated in various clinical trials for relapsed and refractory B cell malignancies. However, this treatment has several disadvantages. Side effects such as cytokine toxicity, tumor lysis syndrome, effects on healthy tissues, B cell hypoplasia, and genotoxicity can be fatal.
To avoid these drawbacks, CAR technology is being applied to other immune cells, such as natural killer (NK) cells. Unlike T cells, NK cells can be more easily fine-tuned to prevent treatment-related toxicity and immune-mediated adverse events. NK cells have great clinical significance because they contribute to graft-vs-leukemia / graft-vs-tumor effect but are not responsible for graft-vs-host disease. NK cells can be generated from various sources, such as cord blood, bone marrow, human embryonic stem cells, and induced pluripotent stem cells.
Primary NK cells engineered to express CAR have potential advantages over CAR-T cells.
Therefore, NK cell lines are attractive for CAR cell therapy.
As the leading cell therapeutics biotech that provides cell therapy related services, Creative Biolabs masters the most advanced CAR technology. With state-of-art CAR development platforms and advanced technologies, Creative Biolabs is capable of offering a broad range of CAR-NK early development services, including CAR engineered T cell biomarker identification and selection, design, construction, and analysis.
All services and products are only for lab research use, not for any clinical diagnosis or treatment.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE